Hermes Vector

Health

Novo Nordisk reports Wegovy lowered BMI in children ages 6 to under 12 in trial

Novo Nordisk says its Wegovy injection significantly lowered body mass index in children ages 6 to under 12 with obesity in a late-stage trial, with no safety concerns related to growth or pubertal development.

By Hermes Vector

Also in: Español · Português · Français · Deutsch · 中文

Checked against 3 sourcesCNBCbreakingthenews.netprnewswire.com
Illustration for: Novo Nordisk reports Wegovy lowered BMI in children ages 6 to under 12 in trial

In brief

  • Novo Nordisk says Wegovy significantly lowered BMI in children ages 6 to under 12 with obesity in a late-stage trial.
  • At week 68, BMI fell 17.4% among children receiving the drug and rose 2.2% among those receiving placebo.
  • 78.7% of children treated with semaglutide had an observed BMI reduction of 10% or more, compared with 0% on placebo.
  • Novo observed no safety concerns related to growth or pubertal development in the children.

Novo Nordisk reports Wegovy lowered BMI in children ages 6 to under 12 in trial

Novo Nordisk released full results from a late-stage trial showing its Wegovy injection helped children ages 6 to under 12 with obesity significantly lower their body mass index. The results were published in The New England Journal of Medicine and presented at ObesityWeek 2026.

Trial results

In the STEP Young trial, 167 children with obesity received either semaglutide or placebo, along with a reduced-calorie diet and increased physical activity. At week 68, the estimated mean percentage change in BMI from baseline was -17.4% with semaglutide and +2.2% with placebo, for an estimated treatment difference of -19.7 percentage points under the efficacy estimand. Under the treatment regimen estimand, the difference was -16.2 percentage points.

More than 85% of the children had class II or III severe obesity at baseline. Nearly half already had at least one obesity-related complication, such as high blood pressure, high cholesterol or sleep apnea.

At week 68, 78.7% of children treated with semaglutide had an observed reduction in BMI of 10% or more under the efficacy estimand, compared with 0% of those receiving placebo. Additionally, 40.4% of children treated with semaglutide were no longer classified as having obesity at week 68 if all children adhered to treatment, compared with 0% of those receiving placebo.

Safety and approval status

Novo said it observed no safety concerns related to growth or pubertal development in the children. The overall safety and tolerability profile was consistent with previous Novo pediatric and adult trials with semaglutide, and no unexpected safety concerns were identified.

Wegovy is already approved to treat obesity in children ages 12 and older. Investigational semaglutide injection is not approved in the United States for use in children under the age of 12, and safety and efficacy are not established for that use.

Why it matters

Childhood obesity can carry serious cardiovascular, metabolic and psychosocial consequences and has had few treatment options for younger children. The World Obesity Federation estimated the disease affected roughly 177 million children and teens ages 5 to 19 worldwide in 2025, a figure projected to rise to 228 million by 2040. Novo said the results offer evidence that Wegovy can potentially fill the treatment gap for children under 12, though the two-year study does not establish whether treating obesity earlier can change its long-term trajectory.


Sources

This article was drafted with AI assistance and checked against the sources above. Company claims are reported as claims. Cover image is AI-generated.

Questions readers ask

What were the results of the STEP Young trial regarding BMI changes in children?
In the STEP Young trial, children ages 6 to under 12 treated with semaglutide saw an estimated mean percentage change in BMI of -17.4% at week 68, compared to +2.2% for those receiving a placebo.
Is Wegovy currently approved for children under the age of 12?
No, investigational semaglutide injection is not approved in the United States for use in children under the age of 12, and safety and efficacy are not established for that use.
What safety concerns were observed in the trial?
Novo Nordisk observed no safety concerns related to growth or pubertal development, and the overall safety profile was consistent with previous pediatric and adult trials with semaglutide.
Why is this trial significant for childhood obesity treatment?
Childhood obesity affects roughly 177 million children and teens ages 5 to 19 worldwide in 2025, and these results offer evidence that Wegovy can potentially fill the treatment gap for children under 12 who have had few options.

The day's checked news, by email

One short email a day with the top stories. Free, and you can unsubscribe in one click.

Or follow for the latest news:

How do you feel about this story?

Comments 0

No comments yet. Start the discussion.

Health

Avian influenza investigation under way at Co Tyrone poultry premises

DAERA is investigating a suspected avian influenza case at a commercial poultry premises in County Tyrone after significant mortality and clinical signs were observed. Samples have been sent to the UK National Reference Laboratory at Weybridge, with results expected on Monday.

Checked against 6 sourcesirishtimes.comagriland.ieireland-live.ie+3 more